Cellular cytotoxicity is mediated by receptors on the surfaces of cytotoxic cells (lysis
promoting receptors) which are specific for cell surface components on target cells. Such …

Cytotoxic cells express specific receptors on their sur-faces by which they distinguish altered
or foreign cells from normal autologous cells. These receptors form multiple links to …

Linking an antitumor cell antibody with an antilymphocyte antibody produces a bifunctional
antibody that can redirect T lymphocytes to lyse tumor cells. Bifunctional antibodies that …

The use of monoclonal antibodies in cancer therapy has been largely unsuccessful in
producing long-term therapeutic effects. In this article, Gundram Jung and Hans Müller …

High‐affinity receptors expressed on the surface of some tumors can be exploited by
chemically conjugating the ligand for the receptor and an antibody against immune effector …

Monoclonal antibodies (mAbs) are emerging as a major modality for both detection and
therapy of various pathological conditions, including malignant disease. Murine monoclonal …

Previous studies have demonstrated that bispecific hybrid antibodies produced by cell-cell
fusion or chemically conjugated heteroaggregates can direct cytotoxic T lymphocytes to kill …

Publisher Summary This chapter discusses the status of cancer treatment using antibody-
drug conjugates. In parallel with definition of differences between normal and neoplastic …

The rationale for the use of antibodies as carriers of cancer chemotherapeutic agents is
based upon: the presence on cells of tumor-associated cell surface antigens (TAA); the …

It has been well established that bispecific antibodies containing anti-T-cell receptor MAbs
crosslinked to anti-tumor MAbs induce T cells to lyse tumor cells, as measured in a 51Cr …